Rapport Therapeutics, Inc.

Contributing Author

Recent Articles by Rapport Therapeutics, Inc.

Aug-24	Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program RAPP GlobeNewswire
Aug-05	Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAPP GlobeNewswire
May-20	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference RAPP GlobeNewswire
May-07	Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update RAPP +7.74% GlobeNewswire
Apr-21	Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting RAPP GlobeNewswire
Apr-01	Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting RAPP GlobeNewswire
Mar-10	Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update RAPP GlobeNewswire
Mar-09	Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China RAPP GlobeNewswire
Feb-24	Rapport Therapeutics to Participate in Upcoming Investor Conferences RAPP GlobeNewswire
Jan-07	Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline RAPP +8.89% GlobeNewswire
Dec-18	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference RAPP GlobeNewswire
Dec-05	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures RAPP GlobeNewswire
Nov-25	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting RAPP GlobeNewswire
Nov-06	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update RAPP GlobeNewswire
Nov-05	Rapport Therapeutics to Participate in Upcoming Investor Conferences RAPP GlobeNewswire
Sep-11	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit RAPP GlobeNewswire
Sep-09	Rapport Announces Pricing of Public Offering of Common Stock RAPP -20.09% GlobeNewswire
Sep-08	Rapport Announces Proposed Public Offering of Common Stock RAPP +119.15% GlobeNewswire
Sep-08	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures RAPP +119.15% GlobeNewswire
Sep-05	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 RAPP -6.45% GlobeNewswire
Aug-07	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update RAPP +5.48% GlobeNewswire
Jun-02	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates RAPP +13.66% RAPP +30.21% GlobeNewswire
May-27	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference RAPP -7.21% GlobeNewswire
May-21	Rapport Therapeutics to Host 2025 Investor and Analyst Day RAPP GlobeNewswire
May-08	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update RAPP GlobeNewswire

Rapport Therapeutics, Inc.

Recent Articles by Rapport Therapeutics, Inc.

Upgrade your Finviz experience